Do you have incurable, metastatic/recurrent head and neck squamous cell carcinoma? If so, you may be able to take part in a study to see if a new drug called petosemtamab is effective. We want to see if petosemtamab works better than the treatments doctors usually use for head and neck squamous cell carcinoma. Compensation provided.

Have you had an organ transplant or hematopoietic cell transplant and have advanced cutaneous squamous cell carcinoma? If so, you might be eligible to take part in a study to see if an investigation drug, RP1, can help treat your skin cancer.

In this study, we want to asses the long-term safety of using a virus to deliver a gene, AAV2-hAQP1, and how effective this gene is at treating dry mouth in people who have received radiation therapy for head and neck cancer.

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

In this study, we want to see what happens when one of the drugs in a 4-drug combination called Dara-RVd is given once a week instead of twice a week. We will look at how this timing change affects the outcome of multiple myeloma with autologous stem cell transplantation. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Have you been diagnosed with Stage III non-small cell lung cancer? Is your cancer advanced and not able to to removed? If so, you might be able to participate in a study that looks at a study drug to see if it can help the radiation treatment work better against your cancer.

Are you a breast cancer survivor? if soy you may be eligible to participate in this research study that is looking at the effectiveness of fisetin and/or exercise on physical function assessed using a 6 minute walking distance in chemotherapy-treated postmenopausal breast cancer survivors

Do you have With Locally Advanced or Metastatic Solid Tumors of the Head or Neck? If so, you may be able to participate in a research study to to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®).

Do you have non small cell lung cancer? Are you currently not on any other treatments for your cancer? If you answered yes, you may be able to take part in a lung cancer medication study.

In this study, we want to learn about a new tool that helps cancer patients make decisions. We also want to understand how patients and doctors communicate when choosing treatments.